Apella raises $80M Series B - January 2026 500,000+ surgical cases supported by Apella AI Fast Company Most Innovative Companies 2025 - Healthcare 16% reduction in OR turnover time MedTech Breakthrough Health Innovation Award 2025 Houston Methodist - 200+ ORs deployed Series B led by HighlandX with Houston Methodist as investor 10% increase in OR case volume for Apella hospital partners David Schummers - Co-Founder & CEO, Apella Technology Apella raises $80M Series B - January 2026 500,000+ surgical cases supported by Apella AI Fast Company Most Innovative Companies 2025 - Healthcare 16% reduction in OR turnover time MedTech Breakthrough Health Innovation Award 2025 Houston Methodist - 200+ ORs deployed Series B led by HighlandX with Houston Methodist as investor 10% increase in OR case volume for Apella hospital partners David Schummers - Co-Founder & CEO, Apella Technology
Profile • San Francisco, CA

David
Schummers

Ambient AI for the room where the stakes are highest

Co-Founder and CEO of Apella Technology. Before ambient AI had a name, he was building it - inside operating rooms, where 40% of expensive surgical time disappears into silence and guesswork. His company has watched over 500,000 surgeries. Hospitals are asking for more.

Co-Founder & CEO $104M Raised Healthcare AI Series B 2026 Fast Company 2025
David Schummers, Co-Founder and CEO of Apella Technology

David Schummers — Apella Technology, San Francisco

$104M
Total Funding Raised
500K+
Surgical Cases Covered
16%
OR Turnover Time Reduction
200+
Houston Methodist ORs Deployed

Watching surgery
like no one ever has

The typical hospital operating room runs at 60% utilization. The other 40% is a story told in waiting - waiting for a room to turn over, for the previous patient to be moved, for the instrument count to be confirmed, for someone to track down the attending. It's expensive, it's exhausting, and until recently, it was invisible.

David Schummers built a camera to watch it all.

Apella's ambient AI platform uses computer vision to capture up to 14 distinct events in every surgical case - patient in, patient out, instrument ready, room clear - and writes structured data back to the electronic health record automatically. No manual logging. No chasing. No paperwork that waits until midnight to get done.

For Schummers, this isn't incremental improvement. It's what he calls the third era of surgical innovation: after open surgery gave way to minimally invasive robotics, data is now the frontier. The question isn't whether AI belongs in the OR - it's whether it's watching closely enough.

"You can't improve what you can't measure. We are developing systematic methods for continuous improvement that can be applied to all types of surgeries and medical procedures."
- David Schummers, Co-Founder & CEO, Apella
Apella's platform adds an average of 2 extra cases per OR per month - and saves 36 overtime minutes per room. Across a system with 50 ORs, that math adds up fast.

The education of a medtech builder

Schummers graduated from Oberlin College in 1999 - a campus better known for cultivating artists and activists than medical device executives. He spent the next two decades moving through the spine of healthcare technology: Medtronic's Spinal and Biologics division, EndoGastric Solutions, Providence Medical Technology. Each stop was a layer of operational knowledge, commercial instinct, and product judgment stacked on the last.

In 2014, he made the bet that defined his trajectory. He joined Auris Health - a surgical robotics startup - as its first commercial executive. Nobody knew then that Johnson & Johnson would eventually write a $5.7 billion check. At the time, it was a calculated leap into early-stage chaos, the kind that either forges something or ends careers.

It forged something. By 2019, when J&J closed the Auris acquisition - at the time, the single largest medtech startup transaction in history - Schummers had helped build the commercial foundation that made the company's value legible to a buyer with a $400 billion market cap.

Three months after the deal closed, he co-founded Apella.

1999
Oberlin College graduate - starts building healthcare industry expertise
2007-2012
Director of Marketing, Medtronic Spinal and Biologics; then VP Marketing at EndoGastric Solutions
2012-2014
VP Marketing at Providence Medical Technology
2014
Joins Auris Health as first commercial executive (VP, Business Development) - a pre-revenue surgical robotics startup
2019
Auris Health acquired by J&J for $5.7B - largest medtech startup exit in history at the time
Oct 2019
Co-founds Apella Technology; also advises Moon Surgical and Eko
2021
Apella closes $21M Series A led by Casdin Capital; publishes "Surgery Enters A Third Era of Innovation"
2025
Fast Company Most Innovative Companies (Healthcare); MedTech Breakthrough Health Innovation Award
Jan 2026
Apella closes $80M Series B led by HighlandX; Houston Methodist joins as investor after deploying 200+ ORs

Fourteen events. One camera.
Zero paperwork.

Put a camera in an operating room and it becomes a witness. Apella's platform reads that footage in real time - tracking patient entry, equipment status, team readiness, case handoffs, room turnover - then sends the right alert to the right person before the bottleneck forms rather than after. The EHR entry writes itself.

For hospital administrators, the platform surfaces a live view of every OR simultaneously: who's ready, what's delayed, which rooms are generating overtime. Predictive case duration forecasting - 24% more accurate than what EHR systems provide alone - lets schedulers stop guessing and start planning. For surgeons and nurses, it means fewer intercom calls, fewer status chases, and more time doing the work they trained for.

Apella OR Impact - Documented Results
16%
Reduction in OR Turnover Time
10%
Increase in OR Case Volume
5%
Average Surgical Volume Increase
+2
Additional Cases per OR Monthly
36 min
Overtime Saved per OR Monthly
15x
Potential ROI Reported

Building conviction, round by round

Dec 2021
Series A
$21M
Jan 2026
Series B
$80M
Total
$104M+

Series B investors: HighlandX (lead) • Vensana Capital • Casdin Capital • K2 HealthVentures • OpAmp Capital • Houston Methodist

The Series B was notable not just for its size. Houston Methodist - after rolling out Apella across 200+ operating rooms in their health system - crossed from customer to capital partner. That kind of institutional endorsement is rare. It's a health system saying: this is not a pilot, this is infrastructure.

The round, led by HighlandX with $80 million in equity and venture debt, brings Apella's total to over $104 million. The company has 110 employees and a growing footprint across major health systems including Tampa General Hospital and the Medical University of South Carolina.

On AI, surgery, and what comes next

"Apella believes that every patient deserves the best possible outcome from surgery. Our technology is aimed at helping each member of the surgical team to do their best job."

"Ambient AI is transforming healthcare. We have applied this technology to the most critical part of the health system: the operating room."

"Using computer vision and machine learning to automatically collect and identify up to 14 surgical case events and autonomously write novel data back to the EHR, Apella ensures healthcare professionals can focus on serving more patients."

"You can't improve what you can't measure. We are developing systematic methods for continuous improvement that can be applied to all types of surgeries and medical procedures."

Three eras of surgery - and Schummers is building the third

Schummers has a framework for where surgery has been and where it's going. Era One: open surgery, the cutting and repairing that defined medicine for centuries. Era Two: minimally invasive surgery and robotics - the laparoscope, the da Vinci, Auris's Monarch - fundamentally reshaping how procedures are performed.

Era Three is data-driven surgical innovation. Not a better robot, not a smaller incision - a smarter room. Systematic measurement enabling systematic improvement. It's the thesis he published in 2021 and has been executing ever since.

He writes regularly for MedCity News and Medical Economics, arguing that ambient AI isn't a feature - it's a fundamental shift in how hospitals can manage their most expensive and consequential real estate. His essays tackle OR utilization, clinician burnout, EHR documentation burden, and the near-term future of AI in healthcare delivery.

Fifty percent of clinician time, by some estimates, goes to documentation and communications rather than care. That's the problem Apella exists to solve - and the mission that's driven Schummers since Apella's first day in October 2019.

Era 1

Open Surgery

Centuries of cutting, repairing, and recovering. Established the foundations of surgical medicine.

Era 2

Minimally Invasive + Robotics

Laparoscopes, robotic systems, Auris's Monarch - smaller incisions, better precision, faster recovery.

Era 3 - Now

Ambient AI + Data Intelligence

Real-time OR awareness, automated documentation, predictive scheduling. Schummers is building this layer.

The record so far

Fast Company's Most Innovative Companies 2025 - Healthcare category. One of the most competitive lists in technology journalism.
MedTech Breakthrough Health Innovation Award 2025 - Industry recognition for Apella's platform and its measurable impact on surgical care.
$80M Series B - January 2026 - Led by HighlandX; Houston Methodist crosses from customer to co-investor after 200+ OR deployment.
500,000+ surgical cases supported - Apella's platform has watched over half a million procedures. The data it's capturing is foundational for what comes next.
Auris Health - $5.7B J&J Acquisition (2019) - As the company's first commercial executive, Schummers helped build the business foundation for the largest medtech startup exit in history at the time.
Published Thought Leadership - Regular contributor to MedCity News and Medical Economics on ambient AI, OR optimization, and the future of surgical care delivery.

Follow the work

Share this profile